Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
站內檢索
:::
▍研究室
:::

幹細胞研究室II

TEL: +886-2-28757434
E-mail: shchiou@vghtpe.gov.tw
邱士華主任
學歷：

國防醫學院 / 醫學系 / 學士     
國立陽明大學 / 臨床醫學研究所 / 博士

 邱士華主任
現職：

臺北榮民總醫院 / 醫學研究部 / 部主任 (2019年1月起)
臺北榮民總醫院 / 眼科 / 主治醫師  (2000年1月起)
國立陽明交通大學 / 醫學院藥理學科暨研究所 / 講座教授  (2017年8月起)
中央研究院 / 基因體研究中心 / 合聘研究員 (2015年4 月起)
台灣細胞醫療協會 / 理事(2020年8月 起))
經歷：

美國哈佛大學醫學院 / 幹細胞中心 / 訪問學者 (2016 / 1 至 2016 /3)

美國Scripps研究所(TSRI) / 分子生物化學部 / 訪問學者 (2007 / 3 至2007 /8)

桃園榮民醫院 / 眼科 / 主治醫師  (2003 / 1 起 2004/12)

美國貝克曼國家研究中心 / 血液骨髓移植研究室 / 博士後研究  (2002 / 2 至2002/4)

臺北榮民總醫院 / 眼科、青光眼科 / 主治醫師 (2000 / 1至 2002/12)

臺北榮民總醫院 / 眼科部 / 臨床研究員 (1998 / 7至 1999)

臺北榮民總醫院 / 眼科部 / 住院醫師、醫師 (1994 / 7 至1998 /6)

臺北榮民總醫院 / 教學研究部 / 主治醫師     

臺北榮民總醫院 / 醫學研究部(基礎研究科) / 科主任 (2013/12 起 -2018/12)
特殊事蹟:

2011年「台灣藥理會-李鎮源教授傑出研究獎」獲獎人

2012年 行政院退輔會台北榮民總醫院醫療創新獎(第一名)

2012年 行政院退輔會台北榮民總醫院醫療最佳論文獎(第二名)

2013年 臺灣生物化學及分子生物學會第二屆年輕學者科技發明創作獎

2013年 第九屆永信李天德青年醫藥科技獎

2013年 科技部(國科會)傑出學術研究獎 (第一次獲獎)

2014年 董大成博士癌症基礎醫學研究傑出獎

2014年 臺北榮民總醫院醫師學術論文獎(第一名)

2015年 行政院退輔會優良醫師獎

2015年 生策會「第12屆國家新創奬」學研新創獎-製藥及新醫療技術組第一名

2016年 臺北榮民總醫院醫療創新獎(第一名)

2016年 科技部傑出學術研究獎 (第二次獲獎)

2017年 科技部「2017未來科技突破獎」「2017未來科技展技術團隊獎」

2018年 亞太國際眼科學會(APAO)暨年度大會  傑出眼科成就獎 (澳洲)

2019年 國家生技醫療產業策進會「第16屆國家新創奬」醫療新創精進獎

2020年 國家生技醫療產業策進會「第17屆國家新創奬」學研新創獎及醫療新創精進獎

2021年 臺北生技跨域卓越優等獎

2021年 國家生技醫療產業策進會「第18屆國家新創奬」醫療新創獎精進獎

2021年 第65屆教育部學術獎 【生物及醫農科學】

2022年 「第32屆王民寧獎」之國內醫藥研究成果對醫藥科技發展、國民健康、國家社會及產業發展傑出貢獻獎【臨床醫學類】

2022年 國家生技醫療產業策進會「第19屆國家新創奬」醫療新創獎精進獎
學術專長:

眼科學與視網膜再生醫學

幹源基因與細胞重新編譯

基因編譯與奈米基因傳遞
研究著作:

(Selected Publications from total of 300 papers)               *: Corresponding author

  1. Ishola AA, Chien CS, Yang YP, Chien Y, Yarmishyn AA, Tsai PH, Chen JC, Hsu PK, Luo YH, Chen YM, Liang KH, Lan YT, Huo TI, Ma HI, Chen MT, Wang ML, Chiou SH*. Oncogenic circRNA C190 Promotes Non-Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway. Cancer Res. 2022 Jan 1;82(1):75-89. (SCI: 12.701 ; RANK=17/242 ;ONCOLOGY
  2. Chien CS, Li Julie YS, YC, Wang ML, Aliaksandr A Yarmishyn, Tsai PH, Juan CC, Phu Neugyn, Cheng HM, Huo TI, Chiou SH *, Chien Shu * (listed as co-corresponding author).METTL3-dependent N6-methyladenosine RNA Modification Mediates the Atherogenic Inflammatory Cascades in Vascular Endothelium. Proc. Natl. Acad. Sci. USA 2021 118 (7) e2025070118 (IF= 9.412; RANK=8/71;Multidisciplinary Sciences)
  3. SJ Chou,Yang P, Ban Q, Yang YP, Wang ML, Chien CS, Chen SJ, Sun N, Zhu Y, Wang F, Zhang RY, Nguyen VQ, Liu Wnfei, Chen M, Jonas SJ, Weiss PS, Tseng HR*, Chiou SH*. Dual Supramolecular Nanoparticle Vectors Enable CRISPR/Cas9‐Mediated Knockin of Retinoschisin 1 Gene—A Potential Nonviral Therapeutic Solution for X‐Linked Juvenile Retinoschisis. Advanced Science 2020 April 16;7(10):1903432 (IF=15.804;RANK=9/103; NANOSCIENCE & NANOTECHNOLOGY )
  4. Yang P, Chou SJ, Li J, Hui W, Liu W, Sun N, Zhang RY, Zhu Y, Tsai ML, Lai HI, Smalley M, Zhang X, Chen J, Romero Z, Liu D, Ke Z, Zou C, Lee CF, Jonas SJ, Ban Q, Weiss PS*, Kohn DB*, Chen K*, Chiou SH*, Tseng HR*.Supramolecular Nanosubstrate-Mediated Delivery System Enables CRISPR/Cas9 Knockin of Hemoglobin Beta Gene for Hemoglobinopathies. Science Advances 2020 Oct 23;6(43):eabb7107  (IF=13.116;RANK=4/71; MULTIDISCIPLINARY SCIENCES)
  5. Tsai PH, Chien Y, Wang ML, Hsu CH, Laurent B, Chou SJ, Chang WC, Chien CS, Li HY, Lee HC, Huo TI, Hung JH, Chen CH, Chiou SH*.Ash2l interacts with Oct4-stemness circuitry to promote super-enhancer-driven pluripotency network. Nucleic Acids Res 2019 Sep 26. (IF= 11.147;RANK= 15/297; BIOCHEMISTRY & MOLECULAR BIOLOGY )
  6. Chen HY, Wang ML, Laurent B, Hsu CH, Chen MT, Lin LT, Shen J, Chang WC, Hsu J, Hung MC, Chen YW, Huang PI, Yang YP, Li CP, Ma HI, Chen CH, Lin WC, Chiou SH*. Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2. Theranostics. 2020 Jan 1; 10(1):201-217. (IF= 8.651;RANK=10 /138; MEDICINE, RESEARCH & EXPERIMENTAL )
  7. Yang TC, Chang CY, Yarmishyn AA, Mao YS, Yang YP, Wang ML, Hsu CC, Yang HY, Hwang DK, Chen SJ, Tsai ML, Lai YH, Tzeng Y, Chang CC, Chiou SH*. Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina. Acta Biomater 2020 Jan 1;101:484-494 (IF= 7.151;RANK= 8/87; ENGINEERING, BIOMEDICAL )
  8. Huang KC, Wang ML, Chen SJ, Kuo JC, Wang WJ, Nhi Nguyen PN, Wahlin KJ, Lu JF, Tran AA, Shi M, Chien Y, Tsai PH, Jane WN, Chang CC, Peng CH, Schlaeger TM, Chiou SH*. Morphological and Molecular Defects in Human Three-Dimensional Retinal Organoid Model of X-Linked Juvenile Retinoschisis. Stem Cell Reports 2019 Nov 12;13(5):906-923. (IF= 6.032;RANK=5 / 29)
  9. Tsai PH, Wang ML, Chang JH, Yarmishyn AA, Nhi Nguyen PN, Chen W, Chien Y, Huo TI, Mou CY, Chiou SH*. Dual Delivery of HNF4α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells. ACS Appl Mater Interfaces 2019;11(22): 19808-19818. (IF=8.758;RANK=33/314)
  10. Liang Y, Wang ML, Chien CS, Yarmishyn AA, Yang YP, Lai WY, Luo YH, Lin YT, Chen YJ, Chang PC, Chiou SH*.Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. Front Immunol. 2020 May 12;11:1022. (IF=5.085; RANK=38/158; IMMUNOLOGY )
  11. Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, Lai WY, Yang DM, Chou SJ, Yang YP, Wang ML, Chiou SH*.A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int J Mol Sci. 2020 Apr 10;21(7):2657. (IF=4.556; RANK=74/297; BIOCHEMISTRY & MOLECULAR BIOLOGY  )
  12. Wang YJ, Larsson M, Huang WT, Chiou SH, Nicholls SJ, Chao JI, and Liu DM. The use of polymer-based nanoparticles and nanostructuredmaterials in treatment and diagnosis of cardiovasculardiseases: Recent advances and emerging designs. Progress in Polymer Science. 2016. 57;153–178.(IF=27.184;RANK= 1/89 ; POLYMER SCIENCE) (Cited in Nature medicine)
  13. Recovery of oxidative stress-induced damage in Cisd2-deficient cardiomyocytes by sustained release of ferulic acid from injectable hydrogel. Cheng YH, Lin FH, Wang CY, Hsiao CY, Chen HC, Kuo HY, Tsai TF, Chiou SH*. Biomaterials 2016 Oct;103:207-18 (IF=10.273;RANK=4/87)
  14. Torchia J et al., &  Chiou SH (listed as Co-authors) & Rutka JT, Jabado N, Huang A. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell. 2016 Dec 12;30(6):891-908. (IF=23.532;RANK= 7/244 ; ONCOLOGY)
  15. Hwang DK, Hsu CC, Chang KJ, Chao D, Sun CH, Jheng YC, A Yarmishyn A, Wu JC, Tsai CY, Wang ML, Peng CH, Chien KH, Kao CL, Lin TC, Woung LC, Chen SJ, Chiou SH*. Artificial intelligence-based decision-making for age-related macular degeneration. Theranostics. 2019 Jan 1;9(1):232-245. (IF= 8.651;RANK= 10/318; MEDICINE, RESEARCH & EXPERIMENTAL )
  16. Yang JW, Tseng ML, Fu YM, Kang CH, Cheng YT, Tzeng CK, Chiou SH, Wu CY, Chen GY. Printable Graphene Oxide Micropatterns for a Bio-Subretinal Chip. Adv Healthc Mater. 2018;7(18): e1800365.
  17. Chien CS, Wang ML, Chu PY, Chang YL, Liu WH, Lan YT, Huang PI, Chen YW, Lo WL, Chiou SH*. Lin28B/Let-7 Regulates Expression of Oct4 and Sox2 and Reprograms Oral Squamous Cell Carcinoma Cells to a Stem-like State. Cancer Res, 2015. 75(12): p. 2553-65. (IF= 9.727;RANK=19 /244; ONCOLOGY )
  18. Jiang BH, Chen WY, Li HY, Chien Y, Chang WC, Hsieh PC, Wu P, Chen CY, Song HY, Chien CS, Sung YJ, and Chiou SH*. CHD1L regulated PARP1-driven Pluripotency and Chromatin Remodeling during the Early-stage Cell Reprogramming. Stem Cells 2015. 33(10): 2961-72. (IF= 6.022;RANK=18 /156; BIOTECHNOLOGY & APPLIED MICROBIOLOGY
  19. Su VY, Chiou SH, Lin CS, Mo MH, Yang KY. Induced Pluripotent Stem Cells Attenuate Endothelial Leakage in Acute Lung Injury via Tissue Inhibitor of Metalloproteinases-1 to Reduce Focal Adhesion Kinase Activity. Stem Cells. 2019 Dec;37(12):1516-1527. IF: 5.614
  20. Hsu CC, Chien KH, Yarmishyn AA, Buddhakosai W, Wu WJ, Lin TC, Chiou SH, Chen JT, Peng CH, Hwang DK, Chen SJ, Chang YL. Modulation of osmotic stress-induced TRPV1 expression rescues human iPSC-derived retinal ganglion cells through PKA. Stem Cell Res Ther 2019 Sep 23; 10(1):284. IF: 5.363 Rank: 32/136
  21. Su VY, Yang KY, Chiou SH, Chen NJ, Mo MH, Lin CS, Wang CT. Induced Pluripotent Stem Cells Regulate Triggering Receptor Expressed on Myeloid Cell-1 Expression and the p38 Mitogen-Activated Protein Kinase Pathway in Endotoxin-Induced Acute Lung Injury. Stem Cells 2019 May;37(5):631-639.
  22. Lu HE, Yang YP, Chen YT, Wu YR, Tsai FT, Hsieh PCH, Chiou SH*.Generation of patient-specific induced pluripotent stem cells from Leber's hereditary optic neuropathy. Stem Cell Res. 2018 31;28:56-60.
  23. Syu JP, Buddhakosai W, Chen SJ, Ke CC, Chiou SH*, Kuo WC*. Supercontinuum source-based multi-contrast optical coherence tomography for rat retina imaging. Biomed Opt Express. 2018;9(12):6132-6144.
  24. Wu YR, Wang AG, Chen YT, Yarmishyn AA, Buddhakosai W, Yang YP, Shen CN, Lee HC, Chiou SH, Peng CH, Chen SJ. Bioactivity and gene expression profiles of hiPSC-generated retinal ganglion cells in MT-ND4 mutated Leber's hereditary optic neuropathy. Exp Cell Res. 2018 Feb 2. 4827(18) 30031-4.
  25. Chou SJ, Ko YL, Yang YH, Yarmishyn AA, Wu YT, Chen CT, Lee HC, Wei YH*, Chiou SH*. Generation of two isogenic human induced pluripotent stem cell lines from a 15 year-old female patient with MERRF syndrome and A8344G mutation of mitochondrial DNA. Stem Cell Res. 2018;30:201-205.
  26. Chuang JH, Yarmishyn AA, Hwang DK, Hsu CC, Wang ML, Yang YP, Chien KH, Chiou SH, Peng CH, Chen SJ. Expression profiling of cell-intrinsic regulators in the process of differentiation of human iPSCs into retinal lineages. Stem Cell Res Ther. 2018 May 11;9(1):140.
  27. Induced pluripotent stem cells reduce neutrophil chemotaxis via activating GRK2 in endotoxin-induced acute lung injury. Su VY, Chiou SH, Lin CS, Chen WC, Yu WK, Chen YW, Chen CY, Yang KY. Respirology. 2017 Aug;22(6):1156-1164.
  28. Musashi-1 Enhances Glioblastoma Cell Migration and Cytoskeletal Dynamics through Translational Inhibition of Tensin3. Chen HY, Lin LT, Wang ML, Laurent B, Hsu CH, Pan CM, Jiang WR, Chen PY, Ma HI, Chen YW, Huang PI, Chiou A, Chiou SH*. Sci Rep. 2017 Aug 18;7(1):8710.
  29. Generation of Functional Dopaminergic Neurons from Reprogramming Fibroblasts by Nonviral-based Mesoporous Silica Nanoparticles. Chang JH, Tsai PH, Wang KY, Chiou SH*, Mou CY*. Sci Rep. 2018 Jan 8; 8(1):11.
  30. Chou SJ, Yu WC, Chang YL, Chen WY, Chang WC, Chien Y, Yen JC, Liu YY, Chen SJ, Wang CY, Chen YH, Niu DM, Lin SJ, Chen JW, Chiou SH*, Leu HB*. Energy utilization of induced pluripotent stem cell-derived cardiomyocyte in Fabry disease. Int J Cardiol. 2017 Apr 1;232:255-263. (IF= 6.338)
  31. Lin TC, Hwang DK, Hsu CC, Peng CH, Wang ML, Chiou SH, Chen SJ. Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study. PLoS One. 2017;12(11):e0188136.
  32. Cheng YH, Chavez E, Tsai KL, Yang KC, Kuo WT, Yang YP, Chiou SH*, Lin FH*. Effects of thermosensitive chitosan-gelatin based hydrogel containing glutathione on Cisd2-deficient chondrocytes under oxidative stress. Carbohydr Polym. 2017;173:17-27.
  33. Song HY, Chiang HC, Tseng WL, Wu P, Chien CS, Leu HB, Yang YP, Wang ML, Jong YJ, Chen CH, Yu WC, Chiou SH*. Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease. Int J Mol Sci. 2016 Dec 13;17(12).
  34. Chou SJ, Tseng WL, Chen CT, Lai YF, Chien CS, Chang YL, Lee HC, Wei YH, and Chiou SH*. Impaired ROS Scavenging System in Human Induced Pluripotent Stem Cells Generated from Patients with MERRF Syndrome. Scientific Reports. 2016. 6: p. 23661.
  35. Tsai PH, Chien Y, Chuang JH, Chou SJ, Chien CH, Lai YH, Li HY, Ko YL, Chang YL, Wang CY, Liu YY, Yang CH, Tsai TF, Lee YY, and Chiou SH*, Dysregulation of Mitochondrial Functions and Osteogenic Differentiation in Cisd2-Deficient Murine Induced Pluripotent Stem Cells. Stem Cells Dev, 2015. (IF: 3.727)
  36. Jiang BH, Tseng WL, Li HY, Wang ML, Chang YL, Sung YJ, and Chiou SH*, Poly(ADP-Ribose) Polymerase 1: Cellular Pluripotency, Reprogramming, and Tumorogenesis. Int J Mol Sci 2015. 16: 15531-45. (IF: 2.862)
  37. Chiou SH*, Jiang BH, Yu YL, Chou SJ, Ping-Hsing Tsai, Chang WC, Chen LK, Chen LH, Yueh Chien Y, Chiou GY. Poly(ADP-ribose) Polymerase 1 Regulates Nuclear Reprogramming and Promotes iPSC Generation without c-Myc. J Exp Med. 2013 Jan. 14;210(1):85-98. (SCI:13.853; Medicine, Research & Experimental 2/112)
  38. Chiou GY, Chien CS, Wang ML, Chen MT, Yang YP, Chien Y, Chang YC, Shen CC, Chio CC, Lu KH, Ma HS, Yu YL, Chen KH, Liu DM, Miller SA, Chen YW, Huang PI, Shih YH, Hung MC, Chiou SH*. Epigenetic Regulation of the MiR142-3p/ Interleukin-6 Circuit in Glioblastoma. Molecular Cell 2013 Dec 12;52(5):693-706. (SCI: 15.28)
  39. Bandey I, Chiou SH, Huang AP, Tsai JC, Tu PH. Progranulin promotes TMZ resistance of glioblastoma by orchestrating DNA repair and tumor stemness. Oncogene 2015. 34(14):1853-64. (SCI: 8.559)
  40. Chiou SH, Jang SF, Mou CY. Mesoporous silica nanoparticles: a potential platform for generation of induced pluripotent stem cells? Nanomedicine 2014;9(4):377-380 (SCI: 5.824)
  41. Chen W, Tsai PH, Hung Y, Chiou SH *, Mou CY*. A Non-Viral Cell Labeling and Differentiation Agent for Induced Pluripotent Stem Cells Based on Mesoporous Silica Nanoparticles. ACS Nano 2013;7:8423-40.(SCI: 13.700)
  42. Larssona M, Huanga WC, Hsiao MH, Wang YJ, Nyden M, Chiou SH, Liu DM. Biomedical applications and colloidal properties of amphiphilically modified chitosan hybrids. Progress in Polymer Science 2013 38;1307–1328 (IF=26.383).
  43. Cheng YH, Hung KH, Tsai TH, Lee CJ, Ku RY, Chiu AW, Chiou SH*, Liu CJ. Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension. Acta Biomaterialia. 2014;10(10):4360-6 (SCI: 7.151)
  44. Hsiao MH, Chiou SH, Larsson M, Hung KH, Liu CJ, Liu DM. A temperature- induced and shear-reversible assembly of latanoprost-loaded amphiphilic chitosan colloids: Characterization and in vivo glaucoma treatment. Acta biomaterialia 2014;10:3188-96.(SCI:7.151)
  45. Yu CC, Tsai LL, Wang ML, Yu CH, Chiou GY, Chou MY, Chiou SH*. miR145 targets the SOX9/ADAM17 axis to inhibit tumor initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res. 2013 Jun 1;73(11):3425-3440. (SCI: 9.329).
  46. Li LF, Liu YY, Yang CT, Chien Y, Wang ML, Twu NF, Wang CY, Chung-Chi Huang CC, Kao KC, Hsu HS, Chiou SH*. Improvement of ventilator-induced lung injury by iPSCs-derived Conditioned Medium via Inhibiting PI3K/Akt Pathway and an IP-10-related Mechanism. Biomaterials. 2013;34:78-91. (IF=10.273)
  47. Chien Y, Liao YW, Liu DM, Lin HL, Chen SJ, Chen HL, Liang CM, Mou CY, Chiou SH*. Corneal repair by human corneal keratocyte- reprogrammed iPSCs and amphiphatic carboxymethyl-hexanoyl chitosan hydrogel. Biomaterials. 2012;33(32):8003-16. (IF=10.273)
  48. Hwang WL, Yang MH, Tsai ML, Lan HY, Su SH, Yang SH, Lan YT, Chiou SH*, Wang HW*. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology. 2011 ;141(1):279-91. (IF=20.773)
  49. Lo WL, Chien Y, Chiou GY, Tseng LM, Hsu HS, Chang YL, Lu KH, Chien CS, Chen YW, Hu FW, Yu CC, Chu PY, Chiou SH*. Nuclear localization signal-enhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous cell carcinoma-derived cancer stem cells. Biomaterials. 2012;3693-709. (IF=10.273)
  50. Chou YT, Hsieh CH, Chiou SH, Hsu CF, Kao YR, Lee CC, Chung CH, Wang YH, Hsu HS, Pang ST, Shieh YS, Wu CW. CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence. Cell Death Differ. 2012;19(12):2015-28. (IF=8.849)
  51. Chiou GY, Cherng JY, Hsu HS, Wang ML, Tsai CM, Lu KH, Chien Y, Tseng LM, Huang PI, Yu CC, Hsu WH, Chiou SH*. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release. 2012;159(2):240-50.(IF=7.633)
  52. Yang YP, Chien Y, Chiou GY, Cherng JY, Wang ML, Lo WL, Chang YL, Huang PI, Chen YW, Shih YH, Chen MT, Chiou SH*. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials. 2012 Feb;33(5):1462-76. (IF=10.273)
  53. Wang ML, Pan CM, Chiou SH, Chen WH, Chang HY, Lee OK, Hsu HS, Wu CW. Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect.Cancer Research. 2012;72(22):6051-64. (SCI: 9.329).
  54. Tsai KS, Yang SH, Lei YP, Tsai CC, Chen HW, Hsu CY, Chen LL, Wang HW, Miller SA, Chiou SH, Hung MC, Hung SC. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology 2011 Sep;141(3):1046-56 (IF=20.773)
  55. Peng CH, Cherng JY, Chiou GY, Chen YC, Chien CH, Kao CL, Chang YL, Chien Y, Chen LK, Liu JH, Chen SJ, Chiou SH* Delivery of Oct4 and SirT1 with cationic polyurethanes-short branch PEI to aged retinal pigment epithelium. Biomaterials. 2011;32(34):9077-88. (IF=10.273)
  56. Li HY, Chien Y, Chen YJ, Chen SF, Chang YL, Chiang CH, Jeng SY, Chang CM, Wang ML, Chen LK, Hung SI, Huo TI, Lee SD, Chiou SH*. Reprogramming induced pluripotent stem cells in the absence of c-Myc for differentiation into hepatocyte-like cells. Biomaterials. 2011 Sep;32(26):5994-6005. (IF=10.273)
  57. Lo WL, Yu CC, Chiou GY, Chen YW, Huang PI, Chien CS, Chang KW, Kao SY, Chiou SH*. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J Pathol. 2011 ;223(4):482-95. (IF=7.585)
  58. Wang CH, Chiou SH (Co-first), Chou CP, Chen YC, Huang YJ, Peng CA. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine-Nanotechnology Biology and Medicine 2011 ;7(1):69-79. (IF=6.930)
  59. Chiou SH, Wang ML, Chou YT, Chen CJ, , Chen YS, Lin TW, Hsu HS, Wu CW. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and EMT. Cancer Res. 2010 ;70:10433-44. (SCI: 9.329)
  60. Chen YW, Chen KH, Huang PI, Chen YC, Hsu HS, Chang KW, Chiou SH*. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma. Mol Cancer Ther. 2010;9:2879-92. (IF=6.107)
  61. Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, Peng WL, Wu JC. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology. 2009 Nov;50(5):1464-74.(IF=14.971)
  62. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JF. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2008 Jul 1;14(13):4085-95.(IF=8.772)
  63. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 2008;10(3):295-305. (IF=20.761)
專利:

1. 美國專利(US Patent: Medium and Device for Proliferation of Stem Cells and Treatment of Cancer-related Stem Cell with Resveratrol (Appl. No: 12/501,279; File date:07/10/09, Approved date:01/23/12; Confirmation No. 4022)

2. 藥物篩選裝置與方法 (中華民國專利: M308081號; 2007.3.21–2016.9.5)

3. 一種篩選幹細胞之裝置 / A Device for Selecting Stem Cells: (中華民國專利: M364083號; 2009.9.1–2018.7.10)

4. 使用白藜蘆醇治療由腫瘤幹細胞引起之非典型畸胎/類橫紋肌細胞瘤的醫藥組合物 (中華民國專利: I 360576; 2012/03/21-2028/08/26)

5. MICRORNA AS A CANCER PROGRESSION PREDICTOR AND ITS USE FOR TREATING CANCER. (美國專利: US8404437B2 公告日2013/3/26)

6. COMPOSITE FOR THERMO- SENSITIVE CELL-TISSUE TRANSPLANTED SCAFFOLD AND USE THEREOF. (美國專利: US8470597 公告日2013/06/25)

7. 感溫性細胞組織移植支架之層合物及其用途(中華民國專利: I 397414; 公告日2013/06/01)

8. GENE DELIVERY OF OCT4 AND SIRT1 AND PHARMACEUTICAL COMPOSITIONS THEREO.(申請國別: 台灣、美國; 申請日期: 2012/8/31)

9. MICRORNA AS A CANCER PROGRESSION PREDICTOR AND ITS USE FOR TREATING CANCER.(申請國別: 中國、歐洲、台灣; 申請日期2012/3/29)

10. METHOD FOR INHIBITING CANCER STEM CELL LIKE PROPERTIES AND CHEMORADIORESISTANT PROPERTIES OF CANCER OR TUMOR CELLS WITH MICRORNA145. (申請國別:台灣、美國; 申請日期2012/11/07)

11. AMPHIPHILIC CHITOSAN NANOGEL AS AN INJECTABLE DELIVERY SYSTEM FOR STEM CELL THERAPY.(申請國別:台灣、美國; 申請日期2012/2/17)

12. METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELLS AND ITS APPLICATION FOR CELL REJUVENATION. (申請國別:美國; 申請日期2013/10/1)

13. A SUSTAINED RELEASING PHARMACEUTICAL COMPOSITION. (申請國別:台灣、美國; 申請日期2015/5/12)

 

 

最後更新：

回到最上